Clinical Trials Browser

Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT04512209 2024-02-28

DCE-MRI

Phase NA Unknown

44 enrolled

GastrointestinalGynecologic

Colonic Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Peritoneal Neoplasms

NCT06281860 2024-02-28

PITHAC

Phase 1 Unknown

39 enrolled

BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT04145388 2024-02-14

Family History Study on Cancer Risk

Phase NA Unknown

18,623 enrolled

BreastGastrointestinalGynecologic

Breast Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms, Genetic Predisposition to Disease

NCT05829057 2024-02-13

The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1

Phase 1 Unknown

10 enrolled

GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

Clinical Trials

CHANCES

DCE-MRI

PITHAC

Family History Study on Cancer Risk

The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1

BENITA

Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors

Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer

STOPOVCA

SUROVA

Study on Symptom Clusters During Chemotherapy in Ovarian Cancer Patients With Different Chinese Medicine Constitution

NEO

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

IMMUNOPARP

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

OPTI-DOSE

Predictors of Ovarian Cancer and Endometrial Cancer for Artificial-Intelligence-Based Screening Tools

MIRRORS-RCTP

New Prognostic Index for Neoadjuvant Chemotherapy Outcome in Patients With Advanced High-grade Serous Ovarian Cancer

Doppler Ultrasound and CT Versus Laparoscopy in Assessment of Ovarian Malignancy

Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer

TOSCA

Factors Affecting the Prognosis of Early Ovarian Cancer

Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments

The Culture of Ovarian Cancer Organoids and Drug Screening

The Culture of Advanced or Recurrent Ovarian Cancer Organoids and Drug Screening

Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence

BEACON

Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer

A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer

SELENIUM

Efficacy and Adverse Effects of Olaparib in Ovarian Cancer.

Huaier Granule in Combination With Nilaparil in Therapy Patients With Stage III/IV BRCA Wild-type Ovarian Cancer

Circulating Tumour DNA as a Marker of Residual Disease & Response to Adjuvant Chemotherapy in Stage I-IV Ovarian Cancer

VATS IN PATIENTS WITH ADVANCED OVARIAN MALIGNANCIES

AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer

A Prospective Cohort Study of 68ga-FAPI-pet-ct Versus FDG-pet-ct for Ovarian Cancer

The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab

Register to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Patients in Austria

NKG2D CAR-NK & Ovarian Cancer

MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer

MITO-7

MITO-12

MITO16/MANGO-2

MITO16MANGO2b

MITO28MaNGOov4

MITO 31

MITO 35a

MRI in Ovarian Tumors